FDA Suspends Biologics License for Ixchiq: A Safety-Driven Pivot
What Happened? On August 22, 2025, the FDA’s Center for Biologics Evaluation and Research (CBER) suspended the biologics license for Ixchiq® (VLA1553)—Valneva’s live-attenuated chikungunya vaccine—citing serious safety concerns. The decision is grounded in evidence that the vaccine may be causing chikungunya-like illness, including encephalitis, hospitalizations, and fatalities.citeturn0search0turn0search1 This move follows a prior May 9, 2025 […]
FDA Launches Real-Time Reporting of Adverse Event Data
A Leap Toward Transparency & Speed On August 22, 2025, the U.S. Food and Drug Administration (FDA) initiated daily publication of adverse event data from its FAERS database—a move designed to revolutionize how safety information is shared with the public U.S. Food and Drug Administration. The FDA Commissioner, Marty Makary, M.D., M.P.H., emphasized that “adverse […]
Qfitlia (fitusiran): a practical, evidence-based look at the newly approved hemophilia prophylaxis
Summary: On March 28, 2025 the U.S. FDA approved Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce bleeding in people 12 years and older with hemophilia A or B — with or without factor inhibitors. Qfitlia is an antithrombin-lowering, subcutaneously administered therapy that aims to restore thrombin generation rather than replacing missing clotting factors. […]
FDA Safety Labeling Change: CORTISPORIN® Ointment — What Changed, What to Update, and How Shudarsana Can Help
What changed (SrLC highlight) On Aug 8, 2025 (SUPPL-86) the FDA approved an update to Adverse Reactions adding the statement: “Skin hyperpigmentation has been reported with polymyxin B containing products.” FDA Access Data+1 This is now explicitly listed alongside other topical corticosteroid/antibiotic local reactions and informs clinicians and patients about a pigmentary risk previously not […]
FDA Safety Labeling Changes for ACTEMRA (tocilizumab): What Changed, PV & Regulatory Impact, and a Playbook for Shudarsana
What changed in the U.S. label Newest update (August 8, 2025): Recent prior update (September 2024): Practical takeaway: Two concurrent risk domains now shape operations—expanded pediatric COVID-19 use (dosing, handling, benefit–risk) and heightened vigilance for severe hypersensitivity/SCARs. FDA Access Data+1 What needs to change internally (manufacturer/MAH “to-do” list) Pharmacovigilance impact Signal detection & case processing […]
Recent Safety Labeling Changes for BYOOVIZ
On August 15, 2025, the FDA approved safety-related labeling changes for BYOOVIZ (ranibizumab-nuna, BLA-761202) FDA Access Data. Key updates include: Impact on Pharmacovigilance Processes 1. Enhanced Signal Detection and Monitoring 2. Case Processing & Reporting 3. Update of Safety Documents 4. Risk Communication Impact on Regulatory Strategy 1. Labeling and Submission Updates 2. Compliance with […]
FDA warns against unapproved epinephrine nasal solutions from BPI Labs & Endo USA: what happened, why it matters, and what to do now
Key takeaways What the FDA alert actually says On Jan 16, 2025, the FDA told health care professionals not to use unapproved epinephrine nasal solutions from BPI Labs and Endo USA because they’re being mistaken for injectable epinephrine. The agency emphasized that the nasal products are not sterile, so any IV administration could cause infection […]
FDA Warning Letter to Vacation, Inc. (Aug 6, 2025): What Happened, Why It Matters, and What Comes Next
On August 6, 2025, the FDA issued a Warning Letter to Vacation, Inc. over its “Classic Whip” sunscreens sold in mousse/whipped-cream style canisters. The agency says these products are misbranded and illegally marketed because the foam dosage form isn’t permitted under today’s OTC sunscreen rules—and because the packaging closely resembles edible whipped cream, creating a […]
Syfovre (pegcetacoplan) — “Slowing the Fade: The First Approved Drug to Slow Geographic Atrophy — Promise, Patents, and Problems”
Below is an in-depth, evidence-based article on Syfovre (active substance pegcetacoplan) that covers: developer and regulatory status, the IP/patent picture, the drug’s benefits, limitations, and the main safety concerns that arose in clinical trials and post-marketing. Key source material is the EMA EPAR/CHMP pages, the OAKS and DERBY Phase-3 trials, Apellis product information, and regulatory […]